SCHEMBL7112784

SCHEMBL7112784

CCCOc1cc(N(NC(=O)CC(=O)c2cccc(-c3cccnc3)c2)C(=O)OC(C)(C)C)ccc1C(F)(F)F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 5/20 0.35
SCN9A Q15858 5/20 0.35
PPARG P37231 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
KMO O15229 1/20 0.34
KMT2A Q03164 1/20 0.34
CYP1A2 P05177 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR2B P41595 1/20 0.33
NOTUM Q6P988 1/20 0.33
MKNK1 Q9BUB5 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
SYK P43405 1/20 0.33
CFTR P13569 1/20 0.33
PLOD2 O00469 1/20 0.33
PLOD3 O60568 1/20 0.33
PLOD1 Q02809 1/20 0.33
CSF1R P07333 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7115204 0.86 KMO (0.36) SCN5ASCN9AKMOCYP1A2HTR2A
SCHEMBL7114425 0.82 PLOD2 (0.42) SCN5ASCN9AKMT2ACYP1A2HTR2A
SCHEMBL7151045 0.81 CNR1 (0.41) TSHRKMOKMT2A
SCHEMBL7044470 0.80 GRM2 (0.35) SYK
SCHEMBL7113378 0.80 ABL1 (0.38) SCN5ASCN9ACSF1RKIT
SCHEMBL5557540 0.79 SCN5A (0.41) SCN5ASCN9ATSHRMAPK1KMO
SCHEMBL5562067 0.78 AAK1 (0.36) SCN9A
SCHEMBL7117074 0.78 ABL1 (0.39) SCN5ASCN9A
SCHEMBL7109630 0.78 CSF1R (0.38) SCN5ASCN9ACSF1RKIT
SCHEMBL7047983 0.77 AAK1 (0.33) SCN5ASCN9AKMOSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1474416-A1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-10 EP disclosed
WO-2003066623-A1 DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2003-08-14 WO disclosed